

DIL Complex, Ghodbunder Road, Thane(W)- 400 610, INDIA.

Tel.: +91-22-6798 0888 : +91-22-6798 0800

Fax: +91-22-6798 0999

Email: contact@dil.ne

www.dil.ne

Unaudited financial results for the quarter ended September 30, 2011. DIL Limited

	EM >				@ For quarter only and not annualised except for year end results	@
% %	6 100,00% 6 59,58%	6 100.00%	6 100,00% 6 59,58%	100.00%	 Percentage to shareholding (as a % of the total shareholding of promoter and promoter group) Percentage to shares (as a % of the total share capital of the Company) 	
3 1,366,293	1,366,293	1,389,233	1,366,293	1,389,233	b) Non-encumbered - Number of shares	
		<u> </u>		Z Z Z		
_					Percentage to sharcholding Promoters and promoter group shareholding Pledged/ Encumbered	
8, 01	926,905 40.42%	903,965 39.42%	926,905 40.42%	903,965 39.42%	5	5519
150 00	37.28	15.19	14.45	8.37 8.37	Basic and diluted EPS (Rs./Share) before extraordinary items Basic and diluted EPS (Rs./Share) after extraordinary items Basic and diluted EPS (Rs./Share) after extraordinary items	
11,320.18		229.32	229,32	229,32		
		348,31	331.27	191.93	16 Net Profit / (Loss) after minority interest and share in associates	
		(47.13) (84.20)		(29.17) (46.23)		
2,799.32		479.64	378.13	267.33		
	944.96	479.64	378.23	267.33	10 Lax expense 11 Net Profit (Loss) from Ordinary Activities after tax (9-10)	_
	1,233.79 288,83	645.86 166.22	502,99 124.76	369.38 102.05		
1,564.67	413.55		189.53		Exceptional nems Exceptional nems	
	820.24	645.86	313.46	369.38		
	62.28	135.64	343.45 29.99	460.25 90.87		
	1.54	28.35	0.40	16.26	Profit from Operations before Other income, interest of Exceptional income Other income	
	2,766.96 880.98	4,264.44 753.15	1,482.60 343.05	2,210.68 443.99		
	101.01 599.83	96.51 1,001.07	59.07 293.85	51.63 529.47		
	173.03	174.09	108.22	74.93		
	199.29	305.04 245.15	101.04	169.28	e) Depreciation/Impairment	
	650.22	882,39	345.33	453,48		
2,082.53	854.26	1,880.71	379.21	1,110.56	a) (Increase)/decrease in stock-in-trade and work in process b) Consumption of raw-materials	
	76.54	(366.62)	155.76	(325 13)	2 Expenditure	
	3,647.94	5,017.59	1,825.65	2,654.67	O) Other Operating income Net sales & other operating income	
7,677.32 194.75	3,558.62 89.32	4,784.59 233.00	1,726.94 98.71	2,502.31 152.36	1 a) Net Sales/ Income from Operations	100000
(Note I)	(Note 1)	(Note 1)	(Note 1)	(Note 1)		
March 31, 2011	September 30, 2010	September 30,	September 30,	September 30,	Sr.No. Particulars	Sr.No
Audited Year Ended	lf year ended	Unaudited Half year ended	arter ended	Unaudited Quarter ended		
		dated	Consolidated			1



SIGNED FOR IDENTIFICATION
BY S. K. Carbos LAssocian S.R. BATLIBOI & ASSOCIATES
MUMBAI

(Rupees in Lal
khs)

		Consolidated	idated		
	Unaudited Quarter ended	uarter ended	. 1	Half year ended	Audited Year Ended
Darticulace	Sentember 30.	September 30,	September 30,	September 30,	March 31,
I di liculais	2011	2010	2011	2010	2011
	(Note 1)	(Note I)	(Note 1)	(Note 1)	(Note 1)
Segment revenue	אד דדר ר	1 499 40	4 270.11	2 986 30	6 550.65
- Bulk drugs/chemicals	11111	310.00	677 05	628 86	1 230 14
- Property	313.17	57.49	2020.5	115.53	265.86
- Treasury	103.76	37,49	203.00	000011	200,000
- Entertainment		2	1 75	1 20	15/10
- Inallocable	1.21	0.99	1.23	07.1	104.10
Total	2,695.90	1,868.87	5,097.36	3,731.89	8,200.75
I you lister commant rayonio	41.23	43.22	79.77	83.95	328.68
Net sales/income from operation	2,654.67	1,825.65	5,017.59	3,647.94	7,872.07
Secret socials (profit/flocs) before interest and tax)					
- Bulk drugs/chemicals	241.98	730 45	20,28	475 10	1,000,00
- Property	101 49	57.49	198.65	113.50	250.62
- Treasury	(17.08)	(14.24)	(37.37)	(29.13)	(64.41)
- Enteranment	(151.27)	(161.89)	(297.86)	(276.35)	(468.21)
- Unallocable	450.70	353.68		900.97	2,123.55
I OBA	6.71	10.63	10.46	19.99	380.63
Less: Inter-segment results	443.99	343,05	753.15	880.98	1,742.92
	90.87	29.99	135.64	62.28	127,79
Add: Thellocable income	16.26	0.40	28.35	1.54	41.26
Exceptional items	0	180 53		413.55	413.55
a) Earn out income (Refer note No. 2)			•		1,564.67
b) Profit on Sale of Investment in Substituty	369.38	502.99	645.86	1,233.79	3,634.61
Profit before tax	00/20	6			
Capital employed (Segment assets Less Segment liabilities)	7,553.33	4,925.98	7,553.33	4,925.98	6,106.77
- buk drugs/cremeas	877,26	691.25	877.26	691.25	
- Property	5,892.71	4,269.18	5,892.71	4,269.18	
- Treasury	116.43	59.89		59.89	
- Entertainment	(2.540.07)	(358.75)	(2	(358.75)	
- Unallocable	11,899.66	9,587.55		9,587.55	11,549.50
Li otal Capital emproyed					

NOTES:

services of sporting and health awareness/education activities DIL Limited ('the Company') is in the business of renting properties, motion film production and distribution and treasmy operations. The Company also has strategic investments in subsidiaries, associates and joint venture which are engaged in manufacturing of bulk drugs, Drug discovery, development services and development of discoidal electrical motor technology and providing

The above unaudited quarterly financial results are presented on a consolidated basis so as to include the operations of the Company's subsidiaries, associates and joint venture

The unaudited consolidated financial result includes the results of a subsidiary, associates and joint venture on the basis of unaudited financial statements prepared by the management

- As per the terms of Share Purchase and Shareholder's Agreement (Agreements) executed by the Company on August 31, 2009 for transferring 70% of paid up equity share capital of Evotec (India) Pvt. Ltd. to Evotec AG, in addition to sales consideration of Rs. 1,117.71 Lakhs, the Company was entitled to Earn out based on Earn out revenue during the twelve months period ended 31st August 2010. Accordingly, during the quarter and half year ended September 30, 2010 the Company had accounted an earn out revenue of Rs. 189.53 Lakhs and Rs. 413.55 Lakhs
- During the current quarter, the Company has executed a Share Purchase Agreement dated September 28, 2011 with Evotec AG, for transfer of 1,09,26,000 fully paid equity shares of Rs. 2/- each i.e. 30% of the paid up equity share capital of Evotec (India) Pvt. Ltd. (EIPL), for a total consideration of Rs. 1,129.33 Lakhs. The transaction was completed on October 05, 2011.
- 4 During the previous year, the Company had entered into Technology Sale and Transfer agreement and transferred the bulk drug technology to Fermenta Biotech Limited for a consideration of Rs
- During the year ended March 31, 2009, Company's subsidiary, Fermenta Biotech Limited (FBL), had entered into an agreement for transfer of the throat lozenge business along with the trademark "Astrasept" and the related moveable assets for a consideration of Rs. 8 Lakhs, to its wholly owned subsidiary G.I.Biotech Private Limited (G.I.). Simultaneously Company has also entered into a "Astrasept" and the related moveable assets for a consideration of Rs. 8 Lakhs, to its wholly owned subsidiary G.I.Biotech Private Limited (G.I.). Simultaneously Company has also entered into a "Astrasept" and the related moveable assets for a consideration of Rs. 8 Lakhs, to its wholly owned subsidiary G.I.Biotech Private Limited (G.I.). Simultaneously Company has also entered into a "Astrasept" and the related moveable assets for a consideration of Rs. 8 Lakhs, as company incorporated under the legal provisions of Cyprus, to transfer its entire shareholding in G.I. in four installments to be completed by February 10, 2009 for a total consideration of USD 400,000. In accordance with the share transfer agreement during the earlier year FBL sold 3750 shares for consideration of USD 400,000 and recorded a profit of Rs 70.64 Lakhs. The time limit stipulated for completion of the share transfer agreement and completion has been extended further to December 150,000 and recorded a profit of Rs 70.64 Lakhs. The time limit stipulated for completion of the share transfer agreement and completion has been extended further to December 150,000 and recorded a profit of Rs 70.64 Lakhs. The time limit stipulated for completion of the share transfer agreement and completion has been extended further to December 150,000 and recorded a profit of Rs 70.64 Lakhs.
- Based on the audited financial statements of the Company for the year ended March 31, 2011, the Company sought clarification from the Reserve Bank of India (RBI) confirming that the Company fulfills the Principal Business Criteria as laid down by RBI. RBI has advised the Company to stop Non-Banking Financial (NBFI) activities and submit a time-bound action plan to reduce financial sasets supported by a Board Resolution. Accordingly, the Board of Directors of the Company in its meeting has decided that the Company does not intend to undertake any NBFI activities. The Company has made submission to RBI for exemption in obtaining 'Certificate of Registration' as a NBFC.

 During the current quarter, the Board of Directors of the Company approved the proposal to redevelop part of its Thane property situated at 'DIL' complex, Ghodbunder Road, Majiwada, Thane (West) 400610. Accordingly, the Company has, subsequent to the quarter, filed the requisite application to Thane Municipal Corporation for seeking permission to that effect.

 Previous year's/ period's figures have been regrouped wherever necessary and are not comparable.
- 7



s.R. Cariboi + Associat SIGNED FOR IDENTIFICATION BATLIBOI & ASSOCIATES MUMBAI

(Rupees in Lakhs)

Particulars		Consolidated	
	Unaudited Half year ended	lf year ended	Audited Year
	September 30,	ber 30,	March 31,
	2011	2010	2011
Shareholders: Funds	229.32	229.32	229.32
(a) Share Capital	11670.34	9,358.23	11,320,18
(i) Reserves and Sulpius	1,723.90	73.67	1,676.77
Loan Runds	3,221.98	1,351.78	1,907.33
Deferred Tax liability (net)	64.12		34.81
Deletied and manner, (may)	16,909.66	11,013.00	15,168,41
	413.33	381.89	413,33
Goodwill on consoling conical work in progress)	6,991.64	4,538.68	6,073.86
Investments	3,854.94	2,644.67	4,113,44
Deferred Tax Assets	,	4/.5/	
Current Assets, Loans and Advances	1 772 91	750.55	1.062.47
(a) Inventories	2,676.95	1,320.08	1,740.03
(b) Sundry debtors	2,389.60	1,316.45	2,408.95
	81.78	38.14	93,63
(d) Other current assets	1,185.24	1,522.35	1,227.66
(e) Douits and avantes			
Less: Current Liabilities and a tovisions	2,213.72	1,189.89	1,500.97
(а) сипели насишее	243.01	357.49	464.58
(D) Provisions			0.59
Viscellaneous experiorure	16,909.66	11,013.00	15,168.41
		-	

10 Total

LIPPOZAVE | LIPPOZAVE |

			Rupees in Lakhs)
	Quarter ended	Quarter ended Half year ended	Year Ended
	September 30, September 30,	September 30,	March 31,
Particulars	2011	2011	2011
	417.47	826.28	3,824.34
Revenue	208.18	394.95	2,723.56
Profit before tax	161 29		2 176 84
Profit after tax	86:101		

- Ξ There were no investor complaints pending at the beginning and at the end of the quarter ended September 30, 2011. 3 (three) complaints were received and resolved during the quarter ended September 30, 2011.

 The above unsudited quarterly results have been taken on record by the Audit Committee and thereafter by the Board of Directors in its meeting held on November 14, 2011 and have been subjected to the limited review by the Statutory Auditors.
- 12

Thane November 14, 2011

SIGNED FOR IDENTIFICATION BY

S. R. Laruboi LAUDCiako

S.R. BATLIBOI & ASSOCIATES
MUMBAI

For DIL Limited

Krishna Datla Managing Director

MANE